Cargando…

Evaluation of the Clinical Effectiveness of the Salmeterol/Fluticasone Fixed-Dose Combination Delivered via the Elpenhaler(®) Device in Greek Patients with Chronic Obstructive Pulmonary Disease and Comorbidities: The AEOLOS Study

Background: Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory lung disease characterized by airflow limitation that is not completely reversible. The fixed-dose combination of salmeterol and fluticasone propionate (SFC) has been approved as a treatment for COPD patients with a history...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steiropoulos, Paschalis, Tryfon, Stavros, Kyriakopoulos, Christos, Bartziokas, Konstantinos, Kostikas, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621702/ https://www.ncbi.nlm.nih.gov/pubmed/34834511 http://dx.doi.org/10.3390/jpm11111159

Ejemplares similares

Adherence and quality of life assessment in patients with asthma treatment with budesonide/formoterol via the Elpenhaler device: the COMPLETE study
por: Exarchos, Konstantinos P., et al.
Publicado: (2022)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Correction to: Adherence and quality of life assessment in patients with asthma treatment with budesonide/formoterol via the Elpenhaler device: the COMPLETE study
por: Exarchos, Konstantinos P., et al.
Publicado: (2022)

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
por: Halpin, David M.G., et al.
Publicado: (2021)

Identification and treatment of T2-low asthma in the era of biologics
por: Kyriakopoulos, Chris, et al.
Publicado: (2021)

The Diagnostic Role of Uric Acid to Creatinine Ratio for the Identification of Patients with Adverse Pulmonary Embolism Outcomes
por: Bartziokas, Konstantinos, et al.
Publicado: (2022)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
por: Gao, Jinming, et al.
Publicado: (2015)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
por: Anzueto, Antonio R., et al.
Publicado: (2018)

Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)

Effectiveness and safety of salmeterol/fluticasone fixed-dose combination delivered through Synchrobreathe(®) in patients with asthma: the real-world EVOLVE study
por: Balamurugan, Santhalingam, et al.
Publicado: (2022)

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
por: Wedzicha, Jadwiga A., et al.
Publicado: (2019)

Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity
por: Bakakos, Petros, et al.
Publicado: (2022)

Lactate dehydrogenase, COVID-19 and mortality
por: Bartziokas, Konstantinos, et al.
Publicado: (2021)

Lactate dehydrogenase, COVID-19 and mortality
por: Bartziokas, Konstantinos, et al.
Publicado: (2021)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age
por: Yoshihara, Shigemi, et al.
Publicado: (2019)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
por: Kirjavainen, Merja, et al.
Publicado: (2018)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine
por: Alyami, Mohammad H., et al.
Publicado: (2022)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
por: Teply, Robyn, et al.
Publicado: (2010)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma
por: Bullone, Michela, et al.
Publicado: (2017)

Dexamethasone/salmeterol/fluticasone-propionate: Invasive pulmonary Aspergillosis: case report
Publicado: (2021)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
por: Tashkin, Donald P., et al.
Publicado: (2021)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
por: Ainali, Nina Maria, et al.
Publicado: (2020)

IL-26 in the Lung and Its Role in COPD Inflammation
por: Bartziokas, Konstantinos, et al.
Publicado: (2022)

Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease
por: Halpern, Rachel, et al.
Publicado: (2011)

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
por: Yasui, Hideki, et al.
Publicado: (2018)

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
por: Ohar, Jill A, et al.
Publicado: (2014)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Greek Guidelines for the Management of COPD, a Proposal of a Holistic Approach Based on the needs of the Greek Community
por: Tzanakis, Nikolaos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ukjdeengvih3t6s1rgnkjvdito